The current chemotherapy for advanced pancreatic cancer including the result of phase II study of irinotecan (CPT-11)

被引：0
|
作者：
Sumii, Toshihiko [1 ]
Fujimori, Nao [1 ]
Funakoshi, Akihiro [1 ]
机构：
[1] Kyushu Natl Canc Ctr, Dept Gastroenterol, Fukuoka, Japan
来源：
PANCREAS | 2008年 / 37卷 / 01期
关键词：
D O I：
10.1097/01.mpa.0000325612.89290.b5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [1] Phase II study of irinotecan (CPT-11) alone in patients (pts) with metastatic pancreatic cancer.
    Funakoshi, A
    Okusaka, T
    Ishii, H
    Sawaki, A
    Ohkawa, S
    Ishikawa, O
    Saitoh, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 338S - 338S
  • [2] Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma
    Poon, D
    Chowbay, B
    Cheung, YB
    Leong, SS
    Tan, EH
    CANCER, 2005, 103 (03) : 576 - 581
  • [3] Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer
    Quintela-Fandino, M
    Gravalos, C
    Gonzalez, E
    Garcia-Velasco, A
    Cortés-Funes, H
    ANTI-CANCER DRUGS, 2005, 16 (01) : 31 - 38
  • [4] Phase II study of irinotecan (CPT-11) in patients with advanced colorectal cancer resistant to 5-fluorouracil based chemotherapy.
    Salinas, P
    Lara, MA
    de Septién, CFM
    Feliu, J
    Espinosa, E
    de Castro, J
    García-Girón, C
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S76 - S76
  • [5] Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer
    Tsunoda, A.
    Yasuda, N.
    Nakao, K.
    Narita, K.
    Watanabe, M.
    Matsui, N.
    Kusano, M.
    ONCOLOGY, 2009, 77 (3-4) : 192 - 196
  • [6] Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer
    Katsube, Takao
    Ogawa, Kenji
    Ichikawa, Wataru
    Fujii, Masashi
    Tokunaga, Akira
    Takagi, Yuh
    Kochi, Misugu
    Hayashi, Kazuhiko
    Kubota, Tetsuro
    Aiba, Keisuke
    Arai, Kuniyoshi
    Terashima, Masanori
    Kitajima, Masaki
    ANTI-CANCER DRUGS, 2007, 18 (05) : 605 - 610
  • [7] Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer
    Stathopoulos, GP
    Rigatos, SK
    Dimopoulos, MA
    Giannakakis, T
    Foutzilas, G
    Kouroussis, C
    Janninis, D
    Aravantinos, G
    Androulakis, N
    Agelaki, S
    Stathopoulos, JG
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2003, 14 (03) : 388 - 394
  • [8] Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma (NPC).
    Poon, D
    Chowbay, B
    Leong, SS
    Cheung, YB
    Toh, CK
    Tay, MH
    Lim, WT
    Tan, EH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 507S - 507S
  • [9] A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix
    Irvin, WP
    Price, FV
    Bailey, H
    Gelder, M
    Rosenbluth, R
    Durivage, HJ
    Potkul, RK
    CANCER, 1998, 82 (02) : 328 - 333
  • [10] Phase II study of metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with refractory metastatic colorectal cancer (MCRC).
    Moiseyenko, V.
    Chubenko, V.
    Protsenko, S.
    Mikhalichenko, T.
    Moiseyenko, F.
    Brezhnev, N.
    Moiseyenko, A.
    Kornilov, A.
    Zueva, E.
    Gorchakova, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345